Drugs / FLX-787-ODT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03334786 | Apr → Aug 2018 | amyotrophic lateral sclerosis | Flex Pharma, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03338114 | Nov 2017 → Aug 2018 | amyotrophic lateral sclerosis | Flex Pharma, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT03254199 | Oct 2017 → Jul 2018 | Charcot-Marie-Tooth disease | Flex Pharma, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLX-787-ODT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03338114 ↗ |
| Route | Oral | “Oral Disintegrating Tablet” NCT03334786 ↗ |